Of 1496 infants with weight data available at 6 months of age, 457 (31%) were exposed to tenofovir (Table 2). The median duration of TDF exposure among those exposed was 21.3 weeks. For infants exposed to TDF in this group, 66% were exposed in the first trimester and 72% were exposed for >12-week duration. Of the 61 infants with age- and sex-adjusted 6 month weight z-scores <fifth percentile, 38% were exposed to TDF in utero. The group of women with infants followed for 6 months was not different than the entire group with infant birth weight available with respect to measured demographic and clinical information.
The multivariable associations of TDF exposures with weight at 6 months are presented in Tables 3 and 4. In comparison to mothers with no TDF exposure, maternal initiation of TDF during the second/third trimester was predictive of low infant weight at 6 months of age based on age- and sex-adjusted weight z-score <fifth percentile. No other significant associations were observed between TDF exposures (any TDF exposure, trimester of the first reported TDF use, and duration of TDF exposure) and other weight measures (absolute weight, age- and sex-adjusted weight z-score). Women who completed at least a high school education were more likely to have a heavier baby in terms of absolute weight and age- and sex-adjusted weight z-score at 6 months of age; babies whose mother had a preeclampsia diagnosis were more likely to have a lower mean absolute weight at 6 months of age than those whose mother did not have a preeclampsia diagnosis. Hispanic women were less likely to have a baby with age- and sex-adjusted weight z-score below the fifth percentile at 6 months of age, compared with non-Hispanic women.
No significant associations were observed between the TDF exposures and the preterm birth outcome. Of the 2099 infants exposed in utero to a combined ARV regimen, there were no differences in preterm birth among infants whose mothers were exposed to a TDF regimen compared with those who were not [117 (18%) vs. 232 (16%), P = 0.26]. Nonobese women, women on antihypertensive therapy during pregnancy, women with preeclampsia, and women with a last reported CD4+ lymphocyte count <200 cells per cubic millimeter during pregnancy were more like to deliver a premature baby.
With the increasing use of TDF by HIV-infected pregnant women, studies examining the safety profile of this drug in exposed neonates are crucial. In this large cohort of infants born to HIV-infected women receiving combination ARV regimens during pregnancy, in utero exposure to tenofovir does not seem to be associated with either infant birth weight or infant growth through 6 months of age. Although there was a marginal association with being underweight at 6 months of age in women who initiated TDF in the second or third trimester, there was no association between duration of maternal TDF use and 6-month weight outcomes. In addition, no association was found with absolute weight or overall age- and sex-adjusted z-score. As expected, women who were obese, diabetic, parous, and without hypertensive diseases of pregnancy tended to have larger babies, both at birth and at 6 months of age.
Although we feel it may not be clinically significant, the isolated finding of lower age- and sex-adjusted weight z-score of <fifth percentile at 6 months of age in infants of women who initiated TDF in the second or third trimester should not be completely overlooked. There are several studies in humans that suggest a delay in effect from ARV exposure not occurring until several months to years after exposure. For instance, febrile seizures were significantly more common in ARV-exposed compared with ARV-unexposed HIV-exposed infants; this effect did not seem until 6–12 months of age.16 In the Women and Infants Transmission Study, the significant difference in CD8+ cell counts by ARV exposure did not seem until 6–24 months.17 In the SMARTTs trial, data at 1 year but not at birth demonstrated lower mean length-for-age and head-circumference-for-age z-scores associated with maternal TDF use.6 More encouraging are results from the Development of AntiRetroviral Therapy in Africa trial,13 which recently reported no evidence that TDF effects growth of infants up to 2 years of age, in a cohort of 226 live births. The clinical relevance and underlying biologic mechanisms of this finding in our study are uncertain. Long-term studies are needed to determine whether this short-term effect on growth has any long lasting impact in childhood or adult life.
Our study has several strengths. We had a large sample size, with large (31%) proportion of infants having tenofovir exposure. In addition, we were able to examine growth in several different ways (absolute weight, underweight, and small for gestational age). We were also able to examine tenofovir exposure by several different measures, to determine if exposure in the first trimester had an effect or if cumulative dose of tenofovir had an effect. Neither seems to have affected fetal or infant growth.
There are, however, some limitations to our study. Tenofovir is eliminated by the kidneys. Renal toxicity with Fanconi syndrome and nephrogenic diabetes insipidus has been reported in children18 and adults19–22 exposed to TDF. There have also been reports of bone toxicity in infant rhesus macaques.23,24 Because of the rarity of these outcomes in infants and reporting bias, our study was unable to examine the effects of tenofovir exposure on either the kidneys or bones. It is reassuring that long-term safety data in rhesus macaques show the renal toxicity to be dose related, with no increased risk of congenital anomalies and good long-term safety data for the offspring.25 However, examining the renal effects of tenofovir exposure in utero is an unmet research need.
Like any cohort study, there is potential for selection bias in the nonrandom allocation of women to TDF as part of their multiagent HAART. In addition, more women exposed to TDF were on a PI containing HAART regimen than those not exposed to TDF, which may lead to confounding in results. Approximately 26% of the infants with birth weight available do not have available 6-month weight values to study. In addition, we were not able to examine growth beyond 6 months. Another limitation is that we only examined growth as a function of weight and not length or head circumference. We recognize this is an important limitation, especially in light of findings from the SMARTT study demonstrating adverse effects on length-for age and head-circumference-for-age z-scores at 1 year,6 despite no observed difference in growth measurements at birth. We also do not have data on maternal adherence to drug therapy, and thus true fetal exposure. Current guidelines from the Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission assign TDF as an alternate agent (not first line) for the treatment of acute HIV infection in pregnant women, whereas it is considered first line treatment in other groups. The need for long-term data on TDF is vital given the rising use in a pregnant population. Long-term growth and developmental outcomes are still needed in children exposed to tenofovir in future large cohorts. There are many challenges to obtaining long-term safety data on drugs used to treat HIV in pregnancy. This population has many socioeconomic and cultural barriers to seeking and maintaining care, there is difficulty in monitoring drug adherence, and this group is often exposed to multiple drug regimens. Although we acknowledge that 45% of TDF-exposed infants were also co-enrolled in the SMARTT study,6 we feel our study still significantly contributes to the literature on this population given the sparse literature on the topic, the challenges to obtaining this information, and the growing use of TDF in clinical obstetric practice. The results of our study present an overall reassuring picture for both fetal growth and neonatal growth as reflected by weight in neonates exposed to TDF in pregnancy. Future studies should be designed to focus on rare neonatal outcomes (fracture, neutropenia, etc.) and long-term delayed effects on infant growth.
P1025 Team Acknowledgment: R. Tuomala, MD, Brigham and Women's Hospital, Boston, MA; E. Smith, MD, National Institute of Allergy and Infectious Diseases Division of AIDS, Pediatric Medicine Branch, Bethesda, MD; K. M. Oden, MHS, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Silver Spring, MD; D. Kacanek, ScD, Harvard School of Public Health, Boston, MA; E. Leister, MS, Harvard School of Public Health, Boston, MA; D. E. Shapiro, PhD, Harvard School of Public Health, Boston, MA; E. A. Barr, CPNP, CNM, MSN, University of Colorado Denver, The Children's Hospital, Denver, CO; D. W. Wara, MD, University of California at San Francisco, San Francisco, CA; A. Bardeguez, MD, MPH, FACOG, University of Medicine and Dentistry of New Jersey, Newark, NJ; S. K. Burchett, MD, MSc, Harvard Medical School, Boston, MA; J. Guiterrez, MD, Bronx-Lebanon Hospital, Bronx, NY; K. Malee, PhD, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; A. M. Stek, MD, Keck School of Medicine, University of Southern California, Los Angeles, CA; P. Tanjutco, MD, Washington Hospital Center, WA, DC; Y. Bryson, MD, David Geffen School of Medicine, University of California, Los Angeles, CA; M. T. Basar, BS, Frontier Science & Technology Research Foundation, Inc, Amherst, NY; A. Hernandez, MA, Frontier Science & Technology Research Foundation, Inc, Amherst, NY; A. Jennings, BS, Frontier Science & Technology Research Foundation, Inc, Amherst, NY; T. R. Cressey, PhD, BSc, Program for HIV Prevention & Treatment, Chang Mai, Thailand; J. Bryant, MPA, Westat, Rockville, MD.
Obstetrics Site Support: 2802 NJ Medical School Clinical Research Site (CRS) (A. D. Bardeguez, MD, MPH; L. Bettica, RN; C. Calilap-Bernardo, RN); 3601 University of California Los Angeles (UCLA)-Los Angeles, CA/Brazil AIDS Consortium (LABAC) CRS; 3801 Texas Children's Hospital CRS; 4001 Chicago Children's CRS; 4101 Columbia IMPAACT CRS (A. Higgins, RN; G. Silva, RN; S. Gaddipati, MD); 4201 University of Miami Pediatric/Perinatal HIV/AIDS CRS (S. Yasin, MD, C. Mitchell, MD, S. Lo Wong, MD, P. Bryan, RN); 4601 University California, San Diego Maternal, Child, and Adolescent HIV CRS (S. A. Spector, MD; A. Hull, MD; M. Caffery, RN, MSN; J. Manning, RN, BSN); 4701 Duke University Medical Center Pediatric CRS (E. Livingston, MD; M. Donnelly, PA; J. Wilson, RN; J. Giner, RN); 5003 Metropolitan Hospital NICHD CRS; 5009 Children's Hospital of Boston NICHD CRS (N. Karthas, RN, MS, CPNP; L. Tucker, BFA; A. Buck, RN; C. Kneut, RN, MS, CPNP); 5011 Boston Medical Center Pediatric HIV Program NICHD CRS; 5012 New York University NICHD CRS (S. Deygoo, MS; A. Kaul, MD; M. Minter, RN; S. Akleh, RN; Supported in part by Grant UL1 TR000038 from the National Center for the Advancement of Translational Science (NCATS), National Institutes of Health); 5013 Jacobi Medical Center Bronx NICHD CRS; 5015 Children's National Medical Center WA DC NICHD CRS; 5017 Seattle Children's Hospital CRS (A. Robson; J. Hitti, MD; C. Venema-Weiss, CNM; A. Klastorin, MSW); 5018 University of South Florida, Tampa NICHD CRS (K. L. Bruder, MD; G. Lewis, RN; D. Casey, RN); 5023 Washington Hospital Center NICHD CRS (S. Parker, MD; R. Scott, MD; P. Tanjutco, MD; V. Emmanuel, BA); 5031 San Juan City Hospital PR NICHD CRS (A. Mimoso, MD; R. Diaz, MD; E. Perez; O. Pereira); 5040 State University of New York Stony Brook NICHD CRS (J. Griffin, NP; P. Ogburn, MD); 5041 Children's Hospital of Michigan NICHD CRS; 5044 Howard University Washington, DC, NICHD CRS; 5045 Harbor UCLA Medical Center NICHD CRS; 5048 University of Southern California, Los Angeles, CA, NICHD CRS (A. Stek, MD; F. Kramer, MD; L. Spencer, MD; A. Kovacs, MD); 5051 University of Florida College of Medicine, Jacksonville NICHD CRS (M. Rathore, MD; I. Delke, MD; G. Thomas, RN; B. Millwood, RN); 5052 University of Colorado, Denver NICHD CRS (A. Katai, MHA; T. Kennedy, FNP-BC; K. Kinzie, FNP-BC; J. Wallace, MSW; Supported by NIH/NCATS Colorado CTSI Grant UL1 TR000154); 5055 South Florida CDC, Ft Lauderdale NICHD CRS; 5083 Rush University Cook County Hospital, Chicago NICHD CRS (J. Schmidt, MD; H. Cejtin, MD; M. McNichols, RN, MSN, CCRC; J. Senka, RN); 5091 University of California, San Francisco NICHD CRS (D. Cohan, MD; This publication was supported by NIH/NCRR UCSF-CTSI Grant UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH); 5092 Johns Hopkins University, Baltimore NCHD CRS (J. Anderson, MD; E. Sheridan-Malone, RN); 5093 Miller Children's Hospital Long Beach, CA, NICHD CRS (C. Tolentino-Balbridge, RN; Janielle Jackson-Alvarez, RN; D. Michalik, DO; J. S. Batra, MD); 5094 University of Maryland Baltimore NICHD CRS (D. Watson, MD; M. Johnson, DDS; C. Hilyard); 5095 Tulane University, New Orleans NICHD CRS (R. Maupin, MD; C. Dola, MD; Y. Luster, RN; S. Bradford, RN); 5096 University of Alabama Birmingham NICHD CRS (A. Tita, MD; M. Parks, CRNP; S. Robbins, BA); 6501 St Jude/UTHSC CRS (E. Thorpe, Jr, MD; K. Knapp, MD; P. Finnie, MSN; N. Sublette, RN, PhD); 6601 University of Puerto Rico Pediatric HIV/AIDS Research Program CRS (C. D. Zorrilla, MD; V. Tamayo-Agrait, MD); 6701 The Children's Hospital of Philadelphia IMPAACT CRS; 6901 Bronx-Lebanon Hospital IMPAACT CRS (R. Wright, MD); 7301 WNE Maternal Pediatric Adolescent AIDS CRS (S. Cormier, RN; K. Luzuriaga, MD; Supported by CTSA Grant 8UL1TR000161).
1. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458–465.
2. Cooper ER, Charurat M, Mofenson L, et al.. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484–494.
3. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
. Accessed October 4, 2013.
6. Siberry GK, Williams PL, Mendez H, et al.. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26:1151–1159.
7. Nurutdinova D, Onen NF, Hayes E, et al.. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother. 2008;42:1581–1585.
8. Eastwood KPK, Melvin A, Venema-Weiss C, et al.. effect of tenofovir on viral suppression during pregnancy in HIV-1 infected women. Am J Obstetrics Gynecol. 2009;2010:S233.
9. Carlevari MZS, Olmscheid B. Use of tenofovir disoproxil fumarate (TDF) and Emtricitabine (FTC) in pregnancy: findings from the antiretroviral pregnancy Registry (APR). Infection. 2009;37:96.
11. Hirt D, Urien S, Ekouevi DK, et al.. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Nature. 2009;85:182–189.
12. Kinai E, Hosokawa S, Gomibuchi H, et al.. Blunted fetal growth by tenofovir in late pregnancy. AIDS. 2012;26:2119–2120.
13. Gibb DM, Kizito H, Russell EC, et al.. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.
14. Olsen IE, Groveman SA, Lawson ML, et al.. New intrauterine growth curves based on United States data. Pediatrics. 2010;125:e214–224.
15. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al.. CDC growth charts: United States. Adv data. 2000;314:1–27.
16. Landreau-Mascaro A, Barret B, Mayaux MJ, et al.. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet. 2002;359:583–584.
17. Pacheco SE, McIntosh K, Lu M, et al.. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. J Infect Dis. 2006;194:1089–1097.
18. Hussain S, Khayat A, Tolaymat A, et al.. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21:1034–1036.
19. Karras A, Lafaurie M, Furco A, et al.. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–1073.
20. Peyriere H, Reynes J, Rouanet I, et al.. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269–273.
21. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324:342–344.
22. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282–284.
23. Tarantal AF, Castillo A, Ekert JE, et al.. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr. 2002;29:207–220.
24. Tarantal AF, Marthas ML, Shaw JP, et al.. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:323–333.
25. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al.. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144–3160.